In a nutshell A year-long study of hospital sink drains found 67 different bacterial species living there, many resistant to ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

We hope to be cured when we stay in hospital. But too often, we acquire new infections there. Such "health-care-associated ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

This guide includes an overview of practices for the prevention and management of sexually transmitted and blood-borne infections (STBBI) by healthcare professionals practicing in public health or ...

A series of reports released today by the European Centre for Disease Prevention and Control (ECDC) show sexually transmitted ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...